Article Per Year (5 Year)
p-Index From 2021 - 2026
0
P-Index
This Author published in this journals
All Journal The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy
Nia Novianti Siregar
Department of Internal medicine, Faculty of Medicine/Dr. Cipto Mangunkusumo General National Hospital, Jakarta
Medicine & Pharmacology

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Comparison between Entecavir and Lamivudine as Hepatitis B Reactivation Prophylaxis in Cancer Patient with Chemotherapy Nia Novianti Siregar; Rachmat Hamonangan; Dana Dharaniyadewi
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 16, No 1 (2015): VOLUME 16, NUMBER 1, April 2015
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (206.741 KB) | DOI: 10.24871/161201551-56

Abstract

Aim: to compare between entecavir and lamivudine as hepatitis B reactivation prophylaxis in cancer patient with chemotherapyMethod: a literature searching in PubMed was done. At the beginning, 8 articles were found. Chosen article in this EBCR were those which compared lamivudine and entecavir directly to lymphoma patient in chemotherapy. Six articles were excluded. Besides PubMed, literature searching was done in Highwire, Cochrane, and Google Scholar too. In Google Scholar, one article that compared entecavir and lamivudine as hepatitis B prophylaxis in cancer patient was found in this study, there were also two multicenter retrospective study that will be appraised.Results: Hepatitis B virus (HBV) reactivation, HBV related hepatitis, and chemotherapy discontinuity as a consequence of Hepatitis B were found to be lower in entecavir groups. Entecavir was more effective in subjects with measured HBV deoxyribonucleic acid (DNA). In unmeasured HBV DNA groups, entecavir were as effective as lamivudine.Conclusion: entecavir were found to be more effective than lamivudine in patient with positive HBsAg or advanced stage of malignancy that were prepared for aggressive chemotherapy regiments. Since entecavir cost was unaffordable, lamivudine still a drug of choice in this situation.
Co-Authors Dana Dharaniyadewi Rachmat Hamonangan